Anatomic Stage IV Breast Cancer AJCC v8 — Expanded Access Programs
Overview
Right2Hope maintains a directory of 39 expanded access programs, clinical trials, and compassionate use pathways listed for Anatomic Stage IV Breast Cancer AJCC v8. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with anatomic stage iv breast cancer ajcc v8 programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 13 programs are currently active or recruiting, with the remaining 26 in other lifecycle stages. Sponsors actively running programs in this area include City of Hope Medical Center, National Cancer Institute (NCI), University of Washington, Mayo Clinic, Roswell Park Cancer Institute, and others.
By recruiting status
Snapshot of where every Anatomic Stage IV Breast Cancer AJCC v8 program currently sits in its lifecycle.
- Active / Recruiting13
- Inactive26
Top sponsors
Organisations running the most Anatomic Stage IV Breast Cancer AJCC v8 programs in the directory.
- City of Hope Medical Center5 programs
- National Cancer Institute (NCI)5 programs
- University of Washington5 programs
- Mayo Clinic4 programs
- Roswell Park Cancer Institute4 programs
- NRG Oncology3 programs
- OHSU Knight Cancer Institute3 programs
- M.D. Anderson Cancer Center2 programs
- Alliance for Clinical Trials in Oncology1 program
- Emory University1 program
Anatomic Stage IV Breast Cancer AJCC v8 programs (39)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Using [18F]FTT PET Scans to Measure PARP Levels in Patients with Metastatic Breast Cancer — University of Washington
- Study on STEMVAC Vaccine with Standard Therapy for Treating Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer — University of Washington
- Adaptive Therapy with Capecitabine for Treating Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer — Mayo Clinic
- Study on Cemiplimab and Y-90 SIR-S Spheres for Treating Liver Metastases in Breast Cancer — City of Hope Medical Center
- Study on Estradiol for Treating ER Beta Positive, Triple Negative Advanced or Metastatic Breast Cancer — Mayo Clinic
- Study on Gemcitabine and Special Immune Cells with or without Naxitamab for Treating Metastatic GD2 Expressing, HER2 Negative Breast Cancer — Margaret Gatti-Mays
- Study on Avoiding the Hippocampus During Radiation for Treating Cancer Spread to the Brain and Spinal Fluid — University of Washington
- Study on Leuprolide and Goserelin for Reducing Estrogen in Pre- or Peri-menopausal Women with Breast Cancer — University of Michigan Rogel Cancer Center
- Study on Photon Craniospinal Irradiation for Treating Cancer Spread to Brain and Spinal Fluid from Breast or Lung Cancer — City of Hope Medical Center
- Study on Tamoxifen and Pegylated Liposomal Doxorubicin for Treating Advanced Triple Negative Breast Cancer — Roswell Park Cancer Institute
- Study Comparing Longer Radiation Therapy to Usual Radiation Therapy for Cancer Spread to the Brain — NRG Oncology
- Study Comparing Proton Radiation Therapy to Standard Radiation for Cancer Spread to Brain and Spinal Fluid — NRG Oncology
- Study on Adding Copanlisib to Eribulin for Treating Metastatic Triple Negative Breast Cancer — National Cancer Institute (NCI)
- Study on 177Lu-DOTATATE for Treating Stage IV or Recurrent Breast Cancer — OHSU Knight Cancer Institute
- Study on a Cancer Vaccine (STEMVAC) with Chemotherapy for Treating PD-L1 Negative Metastatic Triple-Negative Breast Cancer — University of Washington
- Precision Medicine Approach for Treating Advanced Sarcoma, Prostate, Breast, Ovarian, or Pancreatic Cancer — OHSU Knight Cancer Institute
- Study on Abemaciclib and Hormone Therapy for Older Patients with Breast Cancer — City of Hope Medical Center
- Investigational Scan for Imaging HER2+ Breast Cancer with Brain Metastasis — City of Hope Medical Center
- Study on Avapritinib for Treating CKIT or PDGFRA Mutation-Positive Advanced or Metastatic Solid Tumors — M.D. Anderson Cancer Center
- Study on Dendritic Cell Vaccines and Pembrolizumab for Treating Brain Metastasis from Triple Negative or HER2+ Breast Cancer — Roswell Park Cancer Institute
- Study on Finding the Best Dose of GM1 to Reduce or Prevent Numbness or Weakness from Paclitaxel Treatment (Phase II) — Alliance for Clinical Trials in Oncology
- Study on Using Functional Imaging to Predict Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer — University of Washington
- Study on High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for Treating PD-L1 Positive Metastatic Triple Negative Breast Cancer — Emory University
- Study on INCMGA00012 and Pelareorep for Treating Metastatic Triple Negative Breast Cancer (IRENE Study) — Mridula George, MD
- Study on Ivermectin and Balstilimab for Treating Metastatic Triple Negative Breast Cancer — Yuan Yuan
- Study on the Effects of Talazoparib in Patients with Advanced Cancer and DNA Repair Variations — National Cancer Institute (NCI)
- Study on Olaparib with Durvalumab, Selumetinib, Capivasertib, or Ceralasertib for Treating Metastatic Triple Negative Breast Cancer — OHSU Knight Cancer Institute
- Study on Olaparib with Cediranib or AZD6738 for Treating Advanced or Metastatic BRCA Mutated Breast Cancer — M.D. Anderson Cancer Center
- Personalized Vaccine with Pembrolizumab for Treating Advanced Solid Tumors — Mayo Clinic
- Study on Propranolol and Pembrolizumab for Treating Advanced Triple Negative Breast Cancer — Roswell Park Cancer Institute
- Study on Ribociclib, Tucatinib, and Trastuzumab for Treating HER2 Positive Breast Cancer — Jonsson Comprehensive Cancer Center
- Study on Rintatolimod, Celecoxib, and Interferon Alpha 2b with Pembrolizumab for Treating Advanced Triple Negative Breast Cancer — Roswell Park Cancer Institute
- Study on Using Targeted Radiation and Special Imaging for Treating Estrogen Receptor Positive Metastatic Breast Cancer — City of Hope Medical Center
- Study on Targeted Therapy Guided by Genetic Testing for Patients with Advanced Solid Tumors — National Cancer Institute (NCI)
- Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases — SWOG Cancer Research Network
- Study on Adding a Personalized Vaccine to Durvalumab, Tremelimumab, and Chemotherapy for Metastatic Triple Negative Breast Cancer — National Cancer Institute (NCI)
- Study on Adding Whole Brain Radiotherapy with Memory Protection to Targeted Brain Radiation for Cancer Spread to the Brain — NRG Oncology
- Testing Fulvestrant and Binimetinib for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer — National Cancer Institute (NCI)
- Study on TVB-2640 and Trastuzumab with Paclitaxel or Hormone Therapy for Treating HER2 Positive Metastatic Breast Cancer — Mayo Clinic
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Anatomic Stage IV Breast Cancer AJCC v8 to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.